论文部分内容阅读
目的:分析盐酸氨溴索联合阿奇霉素在小儿肺炎治疗中的效果。方法:将2014年7月至2016年8月梁平县人民医院150例住院的支原体肺炎患儿纳为研究对象,随机分为4组,甲组39例,乙、丙、丁组各37例。治疗方式:甲组应用阿奇霉素治疗;乙组应用盐酸氨溴索联合阿奇霉素治疗;丙组应用阿奇霉素治疗,治疗的第4天起联合应用盐酸氨溴索;丁组应用阿奇霉素治疗,治疗的第7天起联合盐酸氨溴索治疗。观察各组治疗情况和不良反应情况。结果:4组患儿在发热持续天数上进行比较,差异无统计学意义(P>0.05),在肺部症状包括咳嗽咳痰持续时间、肺部啰音持续时间和住院总天数比较,乙、丙、丁3组均低于甲组,乙组优于丙组,丙组优于丁组,差异具有统计学意义(P<0.05);各组患儿出现不良反应情况的比较,差异均无统计学意义(P>0.05)。结论:盐酸氨溴索与阿奇霉素联合用药对于小儿肺炎有比较明显的治疗作用,对于发热症状没有明显作用,在肺部症状的治疗上有明显疗效,并且越在治疗早期联合应用,治疗效果越佳。
Objective: To analyze the effect of ambroxol hydrochloride combined with azithromycin in the treatment of pediatric pneumonia. Methods: From July 2014 to August 2016, 150 children with mycoplasmal pneumonia admitted in Liangping People’s Hospital were enrolled and randomly divided into 4 groups: group A (n = 39), group B (group C), and group C (n = 37). Treatment: A group of azithromycin treatment; B group with ambroxol hydrochloride combined with azithromycin treatment group C azithromycin treatment, the first four days of treatment with ambroxol hydrochloride; group of patients with azithromycin treatment, the treatment of the first 7 days From the United ambroxol hydrochloride treatment. Observe the treatment and adverse reactions in each group. Results: There was no significant difference in the duration of fever between the four groups (P> 0.05). The symptoms of lungs including cough and sputum duration, the duration of pulmonary rales and the total number of days of hospital stay, C and D were lower than that of group A, group B was better than group C, group C was better than group D, the difference was statistically significant (P <0.05). There was no difference between the groups Statistical significance (P> 0.05). Conclusions: The combination of ambroxol hydrochloride and azithromycin has a significant therapeutic effect on pediatric pneumonia and has no obvious effect on the symptoms of fever, and has obvious curative effect on the treatment of pulmonary symptoms. The more the combination of ambroxol hydrochloride and azithromycin is, the better the treatment effect is in the early combination therapy .